Drug intelligence / Profile preview

NOV-205

Development stage: Phase 2
Lead developer: Cellectar Biosciences
Modality: Small Molecules

Overview

NOV-205 is a drug developed for the treatment of hepatitis C. It was investigated as a potential therapy for patients with chronic hepatitis C virus (HCV) infection, particularly those who failed standard therapy. The drug was developed by Novelos Therapeutics, Inc. and has been approved in the Russian Federation for the treatment of liver diseases including hepatitis C, but it is not FDA approved[1][2]. The exact mechanism of action is not fully detailed in available public sources.

Brand names: NOV-205NOV205NOV 205
Other names: Oxidized glutathione

Beyond the preview

Go deeper on NOV-205.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NOV-205.

Explore the full profile